STREPTOCOCCAL MULTIENZYME DNA REPLICATION SYSTEM

链球菌多酶 DNA 复制系统

• 批准号: 6292996
• 负责人: JAMES M BULLARD
• 金额: $ 31.38万
• 依托单位: ENZYCO, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-08-01 至 2001-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6292996
• 关键词: DNA replication; Streptococcus pyogenes; antibacterial agents; bacterial genetics; biotechnology; drug design /synthesis /production; drug screening /evaluation; functional /structural genomics; gene expression; gram positive bacteria; high throughput technology; microorganism metabolism; structural genes

DESCRIPTION (Verbatim from Applicant's Abstract):The objective of this proposed study is to build upon a successful phase I study to establish a complete DNA replication system for a prototypical gram-positive pathogen, Streptococcus pyogenes. As in our phase I studies, we plan to continue to exploit available genomic information to permit expression of the S. pyogenes homologs of known replication proteins. We will also exploit templates containing the Streptococcal replication origin to provide a functional assay for Streptococcal replication and initiation factors. Factors not accessible through genomic searches will be isolated by biochemical procedures using their requirement to reconstitute replicative reactions to monitor their purification. The corresponding structural genes for isolated factors will be identified and expressed. The resulting multicomponent replication system will be developed during phase III into a high-throughput assay and compound collections screened for novel lead compounds that can be developed into antibacterials that target the gram-positive replication apparatus. PROPOSED COMMERCIAL APPLICATION: Not Available

描述（逐字摘自申请人摘要）：本提案的目标 研究是在成功的第一阶段研究的基础上建立完整的 DNA 典型革兰氏阳性病原体链球菌的复制系统 化脓性。正如我们的第一阶段研究一样，我们计划继续利用现有的 基因组信息以允许表达已知的化脓性链球菌同源物 复制蛋白。我们还将利用包含以下内容的模板 链球菌复制起点提供功能测定 链球菌复制和起始因子。无法访问的因素 通过基因组搜索将使用其生化程序进行分离 要求重建复制反应以监测其 纯化。孤立因子的相应结构基因将是 识别并表达。由此产生的多组件复制系统将 在第三阶段开发成高通量测定和化合物 筛选可开发成的新型先导化合物的集合 针对革兰氏阳性复制装置的抗菌药物。 拟议的商业应用： 无法使用